Policy and Regulation · 29 September 2026 to 29 September 2026 · 1 headlines · MedCity News
DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens
DreaMed has received FDA clearance for an insulin automation tool driven by continuous glucose monitoring, intended for use with both types of injection regimens for type 2 diabetes.
As it ran
29 September 2026
- DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens MedCity News
More from US healthcare
- STAT Plus: What to expect from UniQure’s upcoming Huntington’s gene therapy readout 29 September 2026
- Ascension Saint Thomas taps new vice president of joint ventures 29 September 2026
- What 340B rebates could mean for hospital cash, staffing, per CEOs 29 September 2026
- Trump's impoundment of congressional spending 28 September 2026
- 901 Dead in Outbreak; 8 Hospitalized After Cheese Consumption; New FDA Approvals 28 September 2026
- CMS launches outcomes-driven quality measurement initiative for states 28 September 2026
- D-SNP, Medicaid integration reshaping insurer growth plans 28 September 2026
- LEARN Behavioral Entity Sues to Stop MassHealth Medicaid Recoupment 28 September 2026